zPREDICTA develops tumor-specific in vitro models for oncology drug discovery and research. Our mission is to accelerate the drug development process for our clients and partners by leveraging our team’s expertise in carcinogenesis, metastasis and the tumor microenvironment. Our complex in vitro models recapitulate the physiological environment of human tissue and thus provide a more clinically relevant testing platform than commonly-used alternatives.
Let us tell you about zPREDICTA.
zPREDICTA’s tumor-specific 3D cell culture models mimic drug responses seen in patients, enabling more successful drug development.
Our unique offerings assist POAI customers with reconstructing 3D tumor architecture and cellular heterogeneity, allowing drug candidates to be tested under native conditions of human tissues. By cultivating a fail-fast approach, and eliminating ineffective compounds early in the development process, zPREDICTA helps facilitate the availability of new therapies for cancer patients.
Julia Kirshner, Ph.D.
With today’s advances in computation and robotics its an exciting time to be a biologist. Never have we been so close to curing human diseases as now. Julia’s vision for zPREDICTA is to create a fully automated end-to-end workflow for drug development. Prior to founding zPREDICTA, Julia held a faculty appointment at the Department of Biological Sciences at Purdue University.
Connect with Julia on LinkedIn
What are our major offerings?
Spheroid models for cancer cell lines from solid tumors and hematological malignancies. Cells cultured in 3D embedded in our proprietary organ-specific ECM provide a far more accurate readout of the drug response compared to the conventional cell culture models.
Co-cultures of tumor epithelium with stroma and immune components. Organ-specific 3D models incorporate epithelial spheroids formed by cancer cell lines, primary cancer-associated fibroblasts (CAFs) or primary non-malignant stroma, with or without immune lymphoid/myeloid immune cells.
Patient-derived models utilizing primary tumor cells grown in 3D in organ-specific ECM with disease-specific medium supplements. The resulting reconstructed tumor microenvironment provides a physiologically relevant platform to assess the efficacy and toxicity of anti-cancer agents.